Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution but also increase access to life-saving products for people around the world.
|Employees (est.) (Mar 2020)||21|
Vaxess Technologies total Funding
Vaxess Technologies latest funding size
Time since last funding
|9 months ago|
Vaxess Technologies investors
|National Science Foundation, National Institutes of Health, Verizon Communications, Bill & Melinda Gates Foundation, The Engine, BioInnovation, BioInnovation Capital|
Vaxess Technologies has 860 Twitter Followers. The number of followers has increased 0.1% month over month and increased 0.6% quarter over quarter
When was Vaxess Technologies founded?
Vaxess Technologies was founded in 2012.
Who are Vaxess Technologies key executives?
Vaxess Technologies's key executives are Michael Schrader and Kathryn Kosuda.
How many employees does Vaxess Technologies have?
Vaxess Technologies has 21 employees.
Who are Vaxess Technologies competitors?
Competitors of Vaxess Technologies include Verona Pharma, Nabriva Therapeutics and Ra Pharmaceuticals.
Where is Vaxess Technologies headquarters?
Vaxess Technologies headquarters is located at 790 Memorial Dr, Cambridge.
Where are Vaxess Technologies offices?
Vaxess Technologies has an office in Cambridge.
How many offices does Vaxess Technologies have?
Vaxess Technologies has 1 office.
Receive alerts for 300+ data fields across thousands of companies